Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

(2017) Nicolas Mottet et al.   EUROPEAN UROLOGY

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016

(2016) Peter R. Carroll et al.   Journal of the National Comprehensive Cancer Network

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

(2016) Claire L Vale et al.   LANCET ONCOLOGY

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) C. Parker et al.   ANNALS OF ONCOLOGY

Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials

(2015) Robert J. van Soest et al.   BMC Medicine

Urological malignancy in Hong Kong: the trend and the practice

(2015) C.-H. Yee et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer

(2013) Zafar Malik et al.   ADVANCES IN THERAPY

Androgen deprivation therapy: past, present and future

(2012) F. Schröder et al.   BJU INTERNATIONAL

Robot-Assisted Radical Prostatectomy in Hong Kong: A Review of 235 Cases

(2011) Kam Hung Sidney Yip et al.   JOURNAL OF ENDOUROLOGY

Recent Advances in Understanding Hormonal Therapy Resistant Prostate Cancer

(2010) K.V. Donkena et al.   CURRENT CANCER DRUG TARGETS

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY